Estrogen Receptor, GATA-3, TTF-1 and KRAS in Endometrial Carcinoma of No Specific Molecular Profile: Prognostic or Diagnostic Markers? - PubMed
a day ago
- #Prognostic Markers
- #Endometrial Carcinoma
- #Estrogen Receptor
- Endometrial carcinoma with no specific molecular profile (NSMP) is heterogeneous with intermediate prognosis.
- European ESGO-ESTRO-ESP guidelines stratify NSMP by histotype and estrogen receptor (ER) status.
- ER expression ≥10% predicts excellent outcome, similar to POLE-mutated cases.
- ER-negativity (<10%) correlates with poor outcome, comparable to p53 abnormal cases.
- ER-positive NSMP cases are mostly low-grade endometrioid carcinomas.
- ER-negative NSMP cases are often non-endometrioid or high-grade endometrioid carcinomas.
- ER-negativity is linked to high-risk histotype and other clinicopathological risk factors.
- ER status does not independently predict disease progression in multivariable analysis.
- No disease-related deaths in rare ER-negative low-grade endometrioid carcinoma cases (n=3).
- GATA3/TTF1 positivity and KRAS mutation found in mesonephric-like and endometrioid carcinomas.
- GATA3, TTF1, and KRAS lack prognostic relevance and limited diagnostic specificity for mesonephric-like carcinoma.